ICLE Comments to USTR on Germany Section 301 Investigation
I. Introduction and Statement of Interest
The International Center for Law & Economics (“ICLE”) is a nonprofit, nonpartisan research center that promotes the use of law & economics methodologies to inform public-policy debates. ICLE welcomes the U.S. Trade Representative’s decision to open this investigation.[1] These comments are the latest in a series of ICLE submissions examining how foreign governments’ pharmaceutical-pricing regimes function as trade distortions that transfer the cost of global drug development to American patients.[2] Because this proceeding asks for a focused record, we compress much of that prior analysis here and cite the fuller treatments—particularly ICLE’s 2025 comments to USTR on foreign pharmaceutical pricing and its 2026 report Don’t Import the Distortion—for readers who want the complete argument and evidence.[3]
Our submission makes three points. First, Germany’s pricing apparatus works as an integrated system to hold reimbursement for innovative medicines below fair market value. This includes the AMNOG benefit-assessment process, a statutory rebate that has just more than doubled, a long-running price freeze, and a new surcharge on pricing confidentiality. Second, analyzed as anticompetitive market distortions, these measures are “unreasonable” within the meaning of Section 301(b) and impose a quantifiable burden on U.S. commerce, even though Germany violates no formal treaty obligation. Third, the appropriate response is a negotiated restructuring of the offending institutions based on the model of the December 2025 U.S.-UK pharmaceutical-pricing agreement and backed, if necessary, by calibrated and conditional trade remedies. What the United States should not do is answer German price suppression by importing administered foreign prices into its own programs.
II. Germany’s Acts, Policies, and Practices Suppress the Prices of Innovative Medicines Below Fair Market Value
Since 2011, every medicine launched in Germany has been routed through an “early benefit assessment” under the Medicines Market Reorganization Act (“AMNOG”). The Federal Joint Committee (“G-BA”), advised by the Institute for Quality and Efficiency in Health Care (“IQWiG”), decides whether a new drug offers an “additional benefit” over a comparator therapy that the G-BA itself selects. That determination then drives the mandatory price negotiation with the national association of sickness funds: an arbitration board imposes terms if the parties fail to agree, and a finding of no additional benefit effectively caps reimbursement at the level of the comparator, which is often a generic.[4]
The procedural deck is essentially stacked against pharmaceutical innovators. The G-BA declines to credit widely accepted surrogate and intermediate endpoints such as progression-free survival, HbA1c, and the like unless sponsors satisfy unusually demanding validation criteria, which systematically depresses the measured “benefit” and, with it, the negotiated price.[5] The predictable output of these choices is that, across a large share of assessed patient subgroups, the G-BA recognizes no additional benefit at all, anchoring prices for genuinely novel therapies to decades-old comparators.[6] A price generated this way is an artifact of administrative design rather than an actual approximation of value.
A. Statutory Rebates Have Just More Than Doubled, Combined With a 15-Year Price Freeze
The Initiation Notice describes draft legislation that would have layered a dynamic, expenditure-linked rebate onto Germany’s existing mandatory manufacturer rebate.[7] But events have overtaken that description, and not in a direction that should be comforting. The GKV-Beitragssatzstabilisierungsgesetz, enacted in July 2026 abandoned the variable mechanism and raised the fixed statutory rebate on patented medicines from 7% to 15.5%, effective January 1, 2027.[8] This single change nearly triples manufacturers’ statutory-rebate burden, from roughly €1.1 billion to €3.2 billion in 2027 alone.[9] And the rebate operates on top of a price moratorium that has frozen list prices, subject only to partial inflation adjustment, continuously since 2010.[10] In short, the conduct under investigation has been codified and enlarged while the present comment period was running.
B. Germany Taxes Pricing Confidentiality, Exporting Its Suppressed Prices Worldwide
Germany’s 2024 legislation reforms nominally permit manufacturers to keep negotiated reimbursement amounts confidential, but only if they accept an additional 9% discount and cover added administrative costs.[11] In essence, this scheme borders on pure rent extraction. Germany conditions a manufacturer’s ability to avoid propagating an artificially low reference price to other jurisdictions on the surrender of additional rents to the German government.
This additional rent extraction is underscored by the fact that Germany is among the most frequently referenced countries in other governments’ external-reference-pricing baskets. A German price suppressed through the AMNOG machinery does not stay in Germany: it becomes the benchmark that ratchets down administered prices across dozens of markets.[12] Charging manufacturers a premium to avoid that propagation is a candid admission of how the system works: Germany monetizes the very spillover that makes its price suppression a matter of legitimate U.S. trade concern. It also moves pricing further from the differential, Ramsey-style structure that economists across the spectrum recognize as the efficient way to finance the global joint costs of pharmaceutical R&D.[13]
III. Germany’s Practices Are Unreasonable and Burden or Restrict U.S. Commerce
Section 301(b) reaches conduct that is “unreasonable or discriminatory” and that “burdens or restricts” U.S. commerce; the statute is explicit that a practice may be unreasonable because it is unfair and inequitable without violating any international legal obligation of the United States.[14] Sustained, state-imposed suppression of pharmaceutical prices that shifts global R&D cost-recovery onto American firms and patients arguably qualified under the statute.[15]
The harder analytical question that is central to the investigation undertaken in this docket is how to distinguish a trading partner’s legitimate health-care regulation from an actionable distortion. Framing the conduct of foreign jurisdictions as “anticompetitive market distortions” (ACMD) may be helpful here. An ACMD is a government intervention that (1) substantially lessens competition; (2) lacks an overriding, legitimate public-policy justification; and (3) confers an artificial advantage on some market participants at others’ expense.[16] Germany’s regime satisfies each element. Its sickness-fund system confronts manufacturers with a monopsonistic single dominant buyer whose “negotiations” are conducted in the shadow of statutory fallbacks, arbitration, and reference-price caps. Cost containment alone cannot supply the justification, because a pricing system that refuses to internalize any meaningful share of the innovation costs its population consumes is not containing costs alone, but is also generating a negative externality on everyone else in the world. Thus the positive local effects of cost containment measures must be judged in proportion to the negative harms they generate abroad.
That conclusion has particular force for Germany, Europe’s largest economy, which plainly has the capacity to pay for the innovation from which its patients benefit.[17] German patients receive American-financed breakthroughs at administered prices, while U.S. firms must recover their global R&D outlays disproportionately from American and other non-German payers. Although, increasingly, it is the case that America alone is being forced to bear this cost. Nothing in this analysis condemns universal coverage or health-technology assessment as such; it condemns the particular institutional choices that disproportionately push prices below fair market value and free-ride on U.S.-funded innovation.
A. The Burden on U.S. Commerce Is Substantial and Quantifiable
USTR’s own figures put U.S. brand-name prices at roughly 3.9 times German levels.[18] That gap is consistent with the broader pattern: U.S. branded prices average 2.56 to 3.44 times those in the EU and OECD,[19] and American consumers supply more than 70% of OECD pharmaceutical profits from a country representing about 40% of OECD output.[20] Critically, the distortion is confined to the branded segment. When prescription costs are weighted by actual prescription volumes, Medicare and Medicaid net costs run roughly 18% below those in Germany and other peer countries, because American generic prices are the lowest in the developed world.[21] The United States does not pay high prices for medicines across the board, but suffers price distortions precisely where foreign administered-pricing systems target their suppression. That asymmetry is the result of deliberate policy choices.
The burden is not merely distributive. A substantial empirical literature ties pharmaceutical innovation to expected revenue: recent estimates imply that innovation by U.S.-headquartered firms responds to U.S. expected revenue with an elasticity of 0.23 to 0.43,[22] and quasi-experimental evidence from Medicare’s durable-medical-equipment price cuts shows that administered price compression translates into steep declines in R&D, patenting, and domestic entry.[23] One estimate on this docket attributes to Germany’s price controls the loss of roughly three new drugs per year.[24] These effects fall on a sector that attracted 13% of U.S. venture capital in 2023 and supports millions of American jobs.[25] And these price controls further erode the practical value of U.S. patent rights, since a patent whose returns a foreign government administratively confiscates is a diminished asset.
IV. The Action USTR Should Take
Negotiation should come first, and it should target institutions rather than outcomes. A durable resolution would include: (1) rescission or phase-down of the 15.5% statutory rebate and a commitment against expenditure-linked escalators; (2) reform of G-BA assessment methods, beginning with recognition of validated surrogate endpoints and neutral comparator selection; (3) elimination of the confidentiality surcharge, so that manufacturers can shield negotiated prices from reference-pricing propagation without paying extractive rents; and (4) a commitment that Germany’s spending on innovative medicines bear a reasonable relationship to its economic capacity—an approach we have previously elaborated in the form of GDP-indexed expenditure floors and binding consultation timelines.[26] The December 2025 agreement in principle with the United Kingdom, under which the UK committed to raise net prices for new medicines by 25% and cap its clawback scheme, in exchange for tariff relief and Section 301 forbearance, demonstrates that this model can produce concrete, measurable reform.[27]
If Germany declines to engage, USTR should deploy remedies that are calibrated to the measured distortion, time-limited, and expressly conditioned on reform—trade measures designed to change the offending institutions, not to punish trade as such. We have previously developed the case for such “distortion-calibrated tariffication” at length in submissions to USTR, and contrasted it with blunt sectoral tariffs that raise costs for American patients without moving foreign policy.[28] Just as important is the boundary condition: Section 301 leverage should never be converted into a domestic most-favored-nation pricing benchmark. Importing Germany’s administered prices into U.S. programs would replicate at home the very distortion this investigation exists to discipline, and would do more damage to pharmaceutical innovation than Germany’s policies themselves.[29] Finally, the Committee should be mindful of the demonstration effect: a disciplined, analytically grounded resolution with Germany will shape the behavior of every other wealthy country now watching whether the United States is willing to defend the returns to its biomedical innovation.[30]
V. Conclusion
Germany’s pricing regime is a set of deliberate institutional choices that hold the prices of innovative medicines below fair market value, export those suppressed prices through reference pricing, and shift the cost of global pharmaceutical innovation onto American patients and firms. Those choices are unreasonable within the meaning of Section 301, and they burden U.S. commerce in ways that are concrete and measurable. USTR should pursue negotiated structural reform on the UK model, hold calibrated remedies in reserve, and decline any path that would import the distortion it has set out to correct.
[1] Initiation of Section 301 Investigation; Hearing; and Request for Public Comments: Germany’s Persistent Underpayment for Innovative Pharmaceutical Products, 91 Fed. Reg. 38,072 (June 24, 2026), https://www.federalregister.gov/documents/2026/06/24/2026-12671/initiation-of-section-301-investigation-hearing-and-request-for-public-comments-germanys-persistent [hereinafter “Initiation Notice”].
[2] See Kristian Stout, ICLE Comments to USTR on Pharmaceutical Pricing, Int’l Ctr. for L. & Econ. (2025), https://laweconcenter.org/resources/icle-comments-to-ustr-on-pharmaceutical-pricing [hereinafter “ICLE Pharmaceutical Pricing Comments”]; Eric Fruits, Lazar Radic, Mario A. Zúñiga & Miko?aj Barczentewicz, ICLE Comments to the USTR on Significant Foreign Trade Barriers § VII, Int’l Ctr. for L. & Econ. (2025), https://laweconcenter.org/resources/icle-comments-to-the-ustr-on-significant-foreign-trade-barriers; Kristian Stout, ICLE Comments on Section 232 Investigation into Pharmaceuticals, Int’l Ctr. for L. & Econ. (2025), https://laweconcenter.org/resources/icle-comments-on-section-232-investigation-into-pharmaceuticals [hereinafter “ICLE Section 232 Comments”].
[3] Kristian Stout, Don’t Import the Distortion: Why MFN Drug Pricing Would Weaken U.S. Innovation, Int’l Ctr. for L. & Econ. (2026), https://laweconcenter.org/resources/dont-import-the-distortion-why-mfn-drug-pricing-would-weaken-u-s-innovation [hereinafter “Stout, Don’t Import the Distortion”].
[4] Sozialgesetzbuch (SGB) v § 35a, https://www.gesetze-im-internet.de/sgb_5/__35a.html; see also Kristian Stout, ICLE Comment on FTC/DOJ Listening Session on Anticompetitive Conduct by Pharmaceutical Companies Impeding Generic or Biosimilar Competition, at 3 (2025), https://laweconcenter.org/resources/icle-comment-on-ftc-doj-listening-session-on-anticompetitive-conduct-by-pharmaceutical-companies-impeding-generic-or-biosimilar-competition (describing the AMNOG assessment-and-negotiation sequence).
[5] See European Federation of Statisticians in the Pharmaceutical Industry (EFSPI), German Benefit Assessment – White Paper: Latest Methodological Requirements in the German Benefit Assessment, at 39 (May 2025), https://www.efspi.org/wp-content/uploads/2025/05/GermanHTA_WhitePaper_2025.pdf.
[6] See Comment of Kristen Jakobsen Osenga, Docket No. USTR-2026-0463 (Aug. 6, 2026) (reporting that no additional benefit is found for more than half of new medicines); cf. vfa, 10 Jahre AMNOG: Eine Bilanz, https://www.vfa.de/de/gesundheit-versorgung/amnog/bilanz-10-jahre-amnog (reporting a lower share when tallied at the level of active ingredients rather than patient subgroups).
[7] Initiation Notice, supra note 1, at 3-4.
[8] See Bundesministerium für Gesundheit, Bundestag beschließt GKV-Beitragssatzstabilisierungsgesetz (July 10, 2026), https://www.bundesgesundheitsministerium.de/ministerium/meldungen/bundestag-beschliesst-gkv-beitragssatzstabilisierunggesetz-pm-10-07-2026; Germany Pushes Through Healthcare Reform Package Despite Pharma’s Drug Discount Resistance, Fierce Pharma (July 2026), https://www.fiercepharma.com/pharma/germany-pushes-through-healthcare-reform-package-despite-pharmas-drug-discount-resistance.
[9] Id. (reporting vfa estimates that the fixed-rebate increase alone will raise the industry’s statutory-rebate burden from roughly €1.1 billion to €3.2 billion in 2027).
[10] SGB v § 130a(3a). The moratorium has been in continuous effect since 2010 and has been repeatedly extended, most recently in connection with the 2026 reform legislation. See Pricing & Reimbursement Laws 2026: Germany, Global Law Experts, https://globallawexperts.com/germany-drug-pricing-reimbursement-2026.
[11] Sozialgesetzbuch Fünftes Buch [SGB V], Dec. 20, 1988, BGBl. I at 2477, as amended, § 130b (1)(c), https://www.gesetze-im-internet.de/sgb_5/__130b.html (Ger.); Initiation Notice, supra note 1, at 3; Brendan Melck, All change in Germany – confidential pricing in, IRP out, Pharmaceutical Technology (Jan. 31, 2025), https://www.pharmaceutical-technology.com/analyst-comment/all-change-germany-confidential-pricing-irp.
[12] See Stout, Don’t Import the Distortion, supra note 3, § II (describing the external-reference-pricing “ratchet”); Kristian Stout, MFN Drug Pricing: Importing the Wrong Cure, Int’l Ctr. for L. & Econ. (July 9, 2026), https://laweconcenter.org/resources/mfn-drug-pricing-importing-the-wrong-cure.
[13] See Patricia M. Danzon, Price Discrimination for Pharmaceuticals: Welfare Effects in the US and the EU, 4 Int’l J. Econ. & Bus. 301 (1997); Stout, Don’t Import the Distortion, supra note 3, § III.A (collecting the Ramsey-pricing literature).
[14] 19 U.S.C. § 2411(b), (d)(3)(B)(i) (an act, policy, or practice is “unreasonable” if, “while not necessarily in violation of, or inconsistent with, the international legal rights of the United States,” it “is otherwise unfair and inequitable”).
[15] See Jeffrey E. Depp, Borrowed Prices: Pharmaceuticals and the American Tab, Truth on the Market (Feb. 25, 2026), https://truthonthemarket.com/2026/02/25/borrowed-prices-pharmaceuticals-and-the-american-tab.
[16] See Shanker A. Singham, Market Distortions and How Best to Deal with Them: Sugar Sector Case Study, Competere (2024); ICLE Pharmaceutical Pricing Comments, supra note 2, § III (applying the three-part ACMD test to foreign pharmaceutical-pricing regimes in detail).
[17] See Comment of the Center for American Principles, Docket No. USTR-2026-0463 (Aug. 6, 2026); Osenga Comment, supra note 6.
[18] Initiation Notice, supra note 1, at 3.
[19]Andrew W. Mulcahy et al., International Prescription Drug Price Comparisons: Current Empirical Estimates and Comparisons with Previous Studies (RAND Corp. Research Report No. RR-2956-ASPEC, 2021), https://www.rand.org/pubs/research_reports/RR2956.html.
[20] Council of Economic Advisers, Funding the Global Benefits to Biopharmaceutical Innovation, at 17 (2020), https://trumpwhitehouse.archives.gov/wp-content/uploads/2020/02/Funding-the-Global-Benefits-to-Biopharmaceutical-Innovation.pdf; World Bank, GDP (Current US$), https://data.worldbank.org/indicator/NY.GDP.MKTP.CD?locations=OE.
[21] Tomas J. Philipson, Deyu Zhang & Qi Zhao, International Comparison of Prices for Drug Prescriptions (Univ. of Chicago Policy Brief, 2025), https://ecchc.economics.uchicago.edu/files/2025/06/Policy-Brief-International-Price-Differences-for-Drug-Prescriptions-June-7.docx.pdf.
[22] Pierre Dubois, Olivier de Mouzon, Fiona Scott Morton & Paul Seabright, Market Size and Pharmaceutical Innovation, 46 RAND J. Econ. 844 (2015); Pierre Dubois, Pharmaceutical Regulation and Incentives for Innovation in an International Perspective, tbl. 4 (Toulouse Sch. of Econ., Working Paper No. 1674, Dec. 2025); see generally Stout, Don’t Import the Distortion, supra note 3, § III.A (surveying this literature and the Congressional Budget Office revenue projections).
[23] Yunan Ji & Parker Rogers, The Long-Run Impacts of Regulated Price Cuts: Evidence from Medicare (NBER Working Paper No. 33083, 2024), https://www.nber.org/papers/w33083.
[24] See Comment of Market Access Solutions LLC, Docket No. USTR-2026-0463 (Aug. 6, 2026) (estimating that German price controls prevent the development of roughly three new drugs per year, and noting average development costs of approximately $2.7 billion and clinical failure rates near 90%).
[25] Osenga Comment, supra note 6 (noting that biopharmaceutical companies attracted 13% of all U.S. venture capital in 2023 and that the sector supports nearly five million U.S. jobs).
[26] See ICLE Pharmaceutical Pricing Comments, supra note 2, § IV (proposing, inter alia, GDP-indexed floors on innovative-medicine expenditures and binding consultation timelines in bilateral instruments).
[27] Press Release, Office of the U.S. Trade Representative, U.S. Government Announces Agreement in Principle with the United Kingdom on Pharmaceutical Pricing (Dec. 1, 2025), https://ustr.gov/about/policy-offices/press-office/press-releases/2025/december/us-government-announces-agreement-principle-united-kingdom-pharmaceutical-pricing; see also CAP Comment, supra note 17; Market Access Solutions Comment, supra note 24.
[28] See Stout, Don’t Import the Distortion, supra note 3, § IV.C (developing the case for distortion-calibrated tariffication); ICLE Section 232 Comments, supra note 2, § IV.B (arguing that responses to foreign distortions should be targeted, temporary, and evidence-based).
[29] See generally Stout, Don’t Import the Distortion, supra note 3; ICLE Pharmaceutical Pricing Comments, supra note 2, § I.
[30] Osenga Comment, supra note 6.